Amid escalating global macroeconomic uncertainties, participants at the recent KoNECT conference in Seoul shared strategies to overcome the current challenges faced by bioventures.

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

In Vivo briefly summarizes the technologies of these recently founded companies: CS-Keys, NERP Technologies, Organ Assist, Sirion Therapeutics, SpeciGen and VEXIM.